Scarica l'app Stockscreener
16.62
4.87%
-0.85
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Precedente Chiudi:
$17.47
Aprire:
$16.48
Volume 24 ore:
6.89M
Relative Volume:
2.01
Capitalizzazione di mercato:
$12.90B
Reddito:
$220.00K
Utile/perdita netta:
$-1.08B
Rapporto P/E:
-11.50
EPS:
-1.4448
Flusso di cassa netto:
$-326.53M
1 W Prestazione:
-1.48%
1M Prestazione:
-32.38%
6M Prestazione:
+2.66%
1 anno Prestazione:
-35.51%
Intervallo 1D:
$16.13
$17.40
Intervallo di 1 settimana:
$15.55
$17.96
Portata 52W:
$13.83
$30.98
Summit Therapeutics Inc Stock (SMMT) Company Profile
Nome
Summit Therapeutics Inc
Settore
Industria
Telefono
305-203-2034
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
16.62 | 13.56B | 220.00K | -1.08B | -326.53M | -1.4448 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-08 | Iniziato | Stifel | Buy |
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-17 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-17 | Iniziato | Barclays | Underweight |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Neutral |
| 2025-07-01 | Iniziato | UBS | Buy |
| 2025-06-11 | Iniziato | Leerink Partners | Underperform |
| 2025-03-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | Goldman | Buy |
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-06 | Iniziato | Jefferies | Buy |
| 2024-11-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-27 | Downgrade | Citigroup | Buy → Neutral |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-07 | Iniziato | Citigroup | Buy |
| 2024-03-26 | Iniziato | Stifel | Buy |
| 2018-06-28 | Downgrade | Janney | Buy → Neutral |
| 2018-05-02 | Iniziato | Janney | Buy |
| 2018-04-12 | Reiterato | Needham | Buy |
| 2018-02-13 | Iniziato | BTIG Research | Buy |
| 2018-01-04 | Iniziato | SunTrust | Buy |
| 2017-12-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-05 | Reiterato | Needham | Buy |
| 2016-09-16 | Iniziato | H.C. Wainwright | Buy |
| 2015-03-30 | Iniziato | Needham | Buy |
| 2015-03-30 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
SMMT Initiates Coverage On Summit Therapeutics -- Rating Underpe - GuruFocus
Summit Therapeutics (SMMT) Downgraded to Neutral Amid Competitiv - GuruFocus
SMMT Downgraded by HC Wainwright & Co. -- Rating Changes to Neut - GuruFocus
Summit Therapeutics (SMMT) Faces Downgrade Amidst Competitive Pr - GuruFocus
Summit Therapeutics Shares Fall After HC Wainwright Downgrade - marketscreener.com
This Summit Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For FridayCentene (NY - Benzinga
Summit downgraded at H.C. Wainwright after Merck data for sac-TMT - Seeking Alpha
Summit Therapeutics Price Target Announced at $7.70/Share by Bernstein - Moomoo
Why is Summit Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Here's Why You Should Add SMMT Stock to Your Portfolio Now - TradingView
Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock By Investing.com - Investing.com Canada
S&P 500 Futures Climb In Premarket Trading; WR Berkley, Summit Therapeutics Lag - Moomoo
H.C. Wainwright downgrades Summit Therapeutics stock rating to neutral By Investing.com - Investing.com Canada
Bernstein Initiates Summit Therapeutics at Underperform - Moomoo
HC Wainwright Downgrades Summit Therapeutics to Neutral From Buy - Moomoo
Summit Therapeutics (SMMT) Faces Scrutiny with Underperform Rati - GuruFocus
Bernstein downgrades Summit Therapeutics stock rating on trial concerns By Investing.com - Investing.com Canada
Summit Therapeutics Inc.Common Stock (NQ: SMMT - The Chronicle-Journal
Cancer Stocks That Are Advancing the Future of Oncology Care - Yahoo! Finance Canada
Summit Therapeutics Inc. (SMMT) Stock Analysis: Healthcare Innovator with Potential 74% Upside - DirectorsTalk Interviews
(SMMT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
A Look At Summit Therapeutics (SMMT) Valuation After HARMONi-3 Trial Risk Highlighted By Analyst Commentary - Yahoo Finance
H.C. Wainwright Reduced its Price Goal on Summit Therapeutics Inc. (SMMT) - Insider Monkey
SMMT Stock Chart | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Summit Therapeutics falls after update on Akeso-partnered lung cancer trial - MSN
8 Most Promising Biotech Stocks to Buy Now - Insider Monkey
SMMT Technical Analysis | Trend, Signals & Chart Patterns | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Summit Therapeutics (SMMT) Is Down 20.1% After Q1 2026 Net Loss Widens Sharply - simplywall.st
Summit Therapeutics Inc (SMMT) News, Articles, Events & Latest Updates - Stocktwits
Q2 EPS Estimate for Summit Therapeutics Boosted by Analyst - MarketBeat
Q2 Earnings Forecast for SMMT Issued By HC Wainwright - MarketBeat
How (SMMT) Movements Inform Risk Allocation Models - Stock Traders Daily
JPM: AKESO (09926.HK) Lung Cancer Trial Final Analysis Likely to Meet Target; Rating Overweight - AASTOCKS.com
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III - BioWorld News
SMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab Setback - Yahoo Finance
Summit Therapeutics: More Uncertainty Heading Into The ASCO Plenary (NASDAQ:SMMT) - Seeking Alpha
Investigation into Summit Therapeutics by Johnson Fistel - Intellectia AI
Summit Therapeutics Inc. Shareholders Are Encouraged to - GlobeNewswire
SMMT Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
H.C. Wainwright cuts Summit Therapeutics stock price target on trial risk - Investing.com Canada
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Cuts Target Price to $23 - Moomoo
We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely - Yahoo Finance
Summit Therapeutics Inc. (SMMT) Stock Analysis: Promising 91% Upside in the Biotech Sector - DirectorsTalk Interviews
Biopharmaceutical News: Summit Therapeutics Stock Plummets After Trial Analysis Misstep - geneonline.com
Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Summit Therapeutics (SMMT) - The Globe and Mail
SMMT Plunges As Summit Therapeutics Stock Suffers 27% Selloff - StocksToTrade
Summit Therapeutics Stock Plunges As Selling Pressure Intensifies - timothysykes.com
Roblox, Spotify, And Robinhood Are Among Top 10 Large-Cap Losers Last Week (April 27-May 1): Are The Others In Your Portfolio? - Benzinga
Summit Therapeutics (SMMT) Receives a Rating Update from a Top Analyst - The Globe and Mail
Summit Therapeutics Flags Significant Going-Concern Risk Amid Cash Shortfall and Uncertain Financing - The Globe and Mail
Summit Therapeutics (SMMT) Is Down 27.0% After HARMONi-6 OS Plenary, BLA Progress And Wider LossesHas The Bull Case Changed? - simplywall.st
Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Summit Therapeutics Inc Azioni (SMMT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
2.98%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):